Teva Pharmaceutical Industries Limited (NYSE: TEVA – Get a rating) saw unusual options trading activity on Tuesday. Investors bought 84,484 call options on the stock. This is a 254% increase from the typical daily volume of 23,889 call options.
Changes to analyst ratings
A number of brokerages have recently commented on TEVA. UBS Group downgraded shares of Teva Pharmaceutical Industries from a “neutral” rating to a “sell” rating in a research report on Friday, November 4. StockNews.com launched a hedge on the shares of Teva Pharmaceutical Industries in a Wednesday, October 12 research note. They set a “buy” rating on the stock. BMO Capital Markets lowered its price target on Teva Pharmaceutical Industries shares from $11.00 to $10.00 and set a “market performance” rating for the company in a Monday, Nov. 7 report. JPMorgan Chase & Co. downgraded shares of Teva Pharmaceutical Industries from a “neutral” rating to an “underweight” rating and cut its price target for the company from $11.00 to $10.00 in a research report from Monday, November 14. Finally, Jefferies Financial Group reiterated a “buy” rating and set a target price of $10.00 on shares of Teva Pharmaceutical Industries in a Friday, October 21 research report. Three investment analysts have assigned the stock a sell rating, three have issued a hold rating and five have assigned the company’s stock a buy rating. According to MarketBeat.com, Teva Pharmaceutical Industries currently has an average rating of “Hold” and an average price target of $10.44.
Teva Pharmaceutical Industries trades up 3.2%
Shares of SUITS YOU traded down $0.28 during Tuesday trading hours, hitting $9.11. The stock recorded trading volume of 242,791 shares, compared to an average trading volume of 10,114,820 shares. The company’s fifty-day simple moving average is $8.55 and its 200-day simple moving average is $8.62. The company has a market capitalization of $10.12 billion, a P/E ratio of -7.61 and a beta of 1.27. The company has a debt ratio of 1.94, a quick ratio of 0.66 and a current ratio of 0.99. Teva Pharmaceutical Industries has a 12-month low of $6.78 and a 12-month high of $11.34.
Teva Pharmaceutical Industries (NYSE: TEVA – Get a rating) last released its quarterly results on Thursday, November 3. The company reported EPS of $0.56 for the quarter, missing the consensus estimate of $0.58 per ($0.02). Teva Pharmaceutical Industries recorded a negative net margin of 8.52% and a positive return on equity of 26.97%. The company posted revenue of $3.60 billion in the quarter, compared to $3.86 billion expected by analysts. Equity research analysts expect Teva Pharmaceutical Industries to post EPS of 2.42 for the current fiscal year.
Teva Pharmaceutical Industries Institutional Trading
A number of institutional investors have recently increased or reduced their stake in TEVA. Private Trust Co. NA bought a new position in shares of Teva Pharmaceutical Industries in the second quarter worth $32,000. Crédit Agricole SA acquired a new equity stake in Teva Pharmaceutical Industries during the second quarter valued at approximately $34,000. Newbridge Financial Services Group Inc. increased its position in shares of Teva Pharmaceutical Industries by 555.6% during the third quarter. Newbridge Financial Services Group Inc. now owns 5,900 shares of the company worth $48,000 after acquiring an additional 5,000 shares in the last quarter. Edmond DE Rothschild Holding SA increased its stake in shares of Teva Pharmaceutical Industries by 213.8% in the third quarter. Edmond DE Rothschild Holding SA now owns 6,678 shares in the company worth $54,000 after acquiring an additional 4,550 shares last quarter. Finally, Allstate Corp bought a new position in Teva Pharmaceutical Industries stock during Q3 valued at around $82,000. 46.22% of the shares are held by hedge funds and other institutional investors.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets and distributes generic drugs, specialty drugs and biopharmaceuticals in North America, Europe and internationally. The company offers sterile products, hormones, high potency drugs and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments and creams.
This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Before you consider Teva Pharmaceutical Industries, you’ll want to hear this.
MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market spreads…and Teva Pharmaceutical Industries was not on the list.
While Teva Pharmaceutical Industries currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.